Literature DB >> 21559551

Expression of the transformed phenotype induced by diverse acting viral oncogenes mediates sensitivity to growth suppression induced by caffeic Acid phenethyl ester (cape).

J Lin1, Z Su, D Grunberger, S Zimmer, P Fisher.   

Abstract

Caffeic acid phenethyl ester (CAPE) displays enhanced growth suppressive and toxic effects toward cloned rat embryo fibroblast (CREF) cells transformed by adenovirus type 5 (Ad5) or the Ad5 E1A transforming gene versus untransformed CREF cells (Su et al, Mol Carcinogen 4: 231-242, 1991). The present study was conducted to determine if transformation of CREF cells with additional oncogenes rendered these cells sensitive to the antiproliferative effect of CAPE. Additionally, studies were conducted to determine if reversion of the transformed phenotype could modify CAPE sensitivity. CAPE displayed increased growth suppressive activity toward CREF cells transformed by a number of oncogenes, including Ha-ras, v-src, v-raf, human papillomavirus type 18 (HPV-18) and human papillomavirus type 51 (HPV-51). Employing Ha-ras-transformed CREF (Ha-ras) and Ha-ras-transformed CREF cells overexpressing the Krev-1 suppressor gene (Ha-ras/Krev-1), evidence for a direct relationship between expression of the transformed phenotype and CAPE sensitivity was demonstrated. Ha-ras/Krev-1 cells displaying a suppression of the transformed phenotype exhibited increased resistance to CAPE-induced growth suppression versus Ha-ras cells, whereas Ha-ras/Krev-1 cells escaping transformation-suppression following in vivo growth in nude mice displayed enhanced sensitivity to growth-suppression induced by CAPE. Similarly, mutant Ad5 (H5hr1)-transformed and v-src-transformed CREF cells displaying a stable reversion in transformation also displayed a reduced sensitivity to CAPE versus their transformed counterparts. These observations indicate a direct relationship between expression of the transformed phenotype and CAPE sensitivity. Elucidation of the mechanism by which CAPE selectively inhibits growth of transformed cells should provide important insights into the critical molecular changes mediating expression of the transformed state and could help identify cellular targets for cancer therapy.

Entities:  

Year:  1994        PMID: 21559551     DOI: 10.3892/ijo.5.1.5

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis.

Authors:  Z Z Su; N I Goldstein; H Jiang; M N Wang; G J Duigou; C S Young; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.

Authors:  Z Su; Y Shi; R Friedman; L Qiao; R McKinstry; D Hinman; P Dent; P B Fisher
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

3.  Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.

Authors:  Siddik Sarkar; Bridget A Quinn; Xue-Ning Shen; Rupesh Dash; Swadesh K Das; Luni Emdad; Alexander L Klibanov; Xiang-Yang Wang; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Oncotarget       Date:  2015-05-10

4.  Effects of caffeic acid phenethyl ester on palatal mucosal defects and tooth extraction sockets.

Authors:  Ahmet Günay; Osman Fatih Arpağ; Serhat Atilgan; Ferhan Yaman; Yusuf Atalay; Izzet Acikan
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

5.  Molecular Characterization and Enhancement of Anticancer Activity of Caffeic Acid Phenethyl Ester by γ Cyclodextrin.

Authors:  Renu Wadhwa; Nupur Nigam; Priyanshu Bhargava; Jaspreet Kaur Dhanjal; Sukriti Goyal; Abhinav Grover; Durai Sundar; Yoshiyuki Ishida; Keiji Terao; Sunil C Kaul
Journal:  J Cancer       Date:  2016-08-11       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.